Cargando…

Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?

BACKGROUND: The delayed percentage attenuation ratio (DPAR) was recently identified as a novel predictor of an early complete response in patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). In this study, we aimed to validate the role of DPAR as a predicti...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Lukas, Hahn, Felix, Jungmann, Florian, Mähringer-Kunz, Aline, Stoehr, Fabian, Halfmann, Moritz C., Pinto dos Santos, Daniel, Hinrichs, Jan, Auer, Timo A., Düber, Christoph, Kloeckner, Roman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753936/
https://www.ncbi.nlm.nih.gov/pubmed/35016731
http://dx.doi.org/10.1186/s40644-022-00446-6
_version_ 1784632174675230720
author Müller, Lukas
Hahn, Felix
Jungmann, Florian
Mähringer-Kunz, Aline
Stoehr, Fabian
Halfmann, Moritz C.
Pinto dos Santos, Daniel
Hinrichs, Jan
Auer, Timo A.
Düber, Christoph
Kloeckner, Roman
author_facet Müller, Lukas
Hahn, Felix
Jungmann, Florian
Mähringer-Kunz, Aline
Stoehr, Fabian
Halfmann, Moritz C.
Pinto dos Santos, Daniel
Hinrichs, Jan
Auer, Timo A.
Düber, Christoph
Kloeckner, Roman
author_sort Müller, Lukas
collection PubMed
description BACKGROUND: The delayed percentage attenuation ratio (DPAR) was recently identified as a novel predictor of an early complete response in patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). In this study, we aimed to validate the role of DPAR as a predictive biomarker for short-, mid-, and long-term outcomes after TACE. METHODS: We retrospectively reviewed laboratory and imaging data for 103 treatment-naïve patients undergoing initial TACE treatment at our tertiary care center between January 2016 and November 2020. DPAR and other washin and washout indices were quantified in the triphasic computed tomography performed before the initial TACE. The correlation of DPAR and radiologic response was investigated. Furthermore, the influence of DPAR on the 6-, 12-, 18-, and 24-month survival rates and the median overall survival (OS) was compared to other established washout indices and estimates of tumor burden and remnant liver function. RESULTS: The DPAR was significantly of the target lesions (TLs) with objective response to TACE after the initial TACE session was significantly higher compared to patients with stable disease (SD) or progressive disease (PD) (125 (IQR 118–134) vs 110 (IQR 103–116), p < 0.001). Furthermore, the DPAR was significantly higher in patients who survived the first 6 months after TACE (122 vs. 115, p = 0.04). In addition, the number of patients with a DPAR > 120 was significantly higher in this group (n = 38 vs. n = 8; p = 0.03). However, no significant differences were observed in the 12-, 18-, and 24-month survival rates after the initial TACE. Regarding the median OS, no significant difference was observed for patients with a high DPAR compared to those with a low DPAR (18.7 months vs. 12.7 months, p = 0.260). CONCLUSIONS: Our results confirm DPAR as the most relevant washout index for predicting the short-term outcome of patients with HCC undergoing TACE. However, DPAR and the other washout indices were not predictive of mid- and long-term outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-022-00446-6.
format Online
Article
Text
id pubmed-8753936
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87539362022-01-18 Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis? Müller, Lukas Hahn, Felix Jungmann, Florian Mähringer-Kunz, Aline Stoehr, Fabian Halfmann, Moritz C. Pinto dos Santos, Daniel Hinrichs, Jan Auer, Timo A. Düber, Christoph Kloeckner, Roman Cancer Imaging Research Article BACKGROUND: The delayed percentage attenuation ratio (DPAR) was recently identified as a novel predictor of an early complete response in patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). In this study, we aimed to validate the role of DPAR as a predictive biomarker for short-, mid-, and long-term outcomes after TACE. METHODS: We retrospectively reviewed laboratory and imaging data for 103 treatment-naïve patients undergoing initial TACE treatment at our tertiary care center between January 2016 and November 2020. DPAR and other washin and washout indices were quantified in the triphasic computed tomography performed before the initial TACE. The correlation of DPAR and radiologic response was investigated. Furthermore, the influence of DPAR on the 6-, 12-, 18-, and 24-month survival rates and the median overall survival (OS) was compared to other established washout indices and estimates of tumor burden and remnant liver function. RESULTS: The DPAR was significantly of the target lesions (TLs) with objective response to TACE after the initial TACE session was significantly higher compared to patients with stable disease (SD) or progressive disease (PD) (125 (IQR 118–134) vs 110 (IQR 103–116), p < 0.001). Furthermore, the DPAR was significantly higher in patients who survived the first 6 months after TACE (122 vs. 115, p = 0.04). In addition, the number of patients with a DPAR > 120 was significantly higher in this group (n = 38 vs. n = 8; p = 0.03). However, no significant differences were observed in the 12-, 18-, and 24-month survival rates after the initial TACE. Regarding the median OS, no significant difference was observed for patients with a high DPAR compared to those with a low DPAR (18.7 months vs. 12.7 months, p = 0.260). CONCLUSIONS: Our results confirm DPAR as the most relevant washout index for predicting the short-term outcome of patients with HCC undergoing TACE. However, DPAR and the other washout indices were not predictive of mid- and long-term outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-022-00446-6. BioMed Central 2022-01-11 /pmc/articles/PMC8753936/ /pubmed/35016731 http://dx.doi.org/10.1186/s40644-022-00446-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Müller, Lukas
Hahn, Felix
Jungmann, Florian
Mähringer-Kunz, Aline
Stoehr, Fabian
Halfmann, Moritz C.
Pinto dos Santos, Daniel
Hinrichs, Jan
Auer, Timo A.
Düber, Christoph
Kloeckner, Roman
Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?
title Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?
title_full Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?
title_fullStr Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?
title_full_unstemmed Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?
title_short Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?
title_sort quantitative washout in patients with hepatocellular carcinoma undergoing tace: an imaging biomarker for predicting prognosis?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753936/
https://www.ncbi.nlm.nih.gov/pubmed/35016731
http://dx.doi.org/10.1186/s40644-022-00446-6
work_keys_str_mv AT mullerlukas quantitativewashoutinpatientswithhepatocellularcarcinomaundergoingtaceanimagingbiomarkerforpredictingprognosis
AT hahnfelix quantitativewashoutinpatientswithhepatocellularcarcinomaundergoingtaceanimagingbiomarkerforpredictingprognosis
AT jungmannflorian quantitativewashoutinpatientswithhepatocellularcarcinomaundergoingtaceanimagingbiomarkerforpredictingprognosis
AT mahringerkunzaline quantitativewashoutinpatientswithhepatocellularcarcinomaundergoingtaceanimagingbiomarkerforpredictingprognosis
AT stoehrfabian quantitativewashoutinpatientswithhepatocellularcarcinomaundergoingtaceanimagingbiomarkerforpredictingprognosis
AT halfmannmoritzc quantitativewashoutinpatientswithhepatocellularcarcinomaundergoingtaceanimagingbiomarkerforpredictingprognosis
AT pintodossantosdaniel quantitativewashoutinpatientswithhepatocellularcarcinomaundergoingtaceanimagingbiomarkerforpredictingprognosis
AT hinrichsjan quantitativewashoutinpatientswithhepatocellularcarcinomaundergoingtaceanimagingbiomarkerforpredictingprognosis
AT auertimoa quantitativewashoutinpatientswithhepatocellularcarcinomaundergoingtaceanimagingbiomarkerforpredictingprognosis
AT duberchristoph quantitativewashoutinpatientswithhepatocellularcarcinomaundergoingtaceanimagingbiomarkerforpredictingprognosis
AT kloecknerroman quantitativewashoutinpatientswithhepatocellularcarcinomaundergoingtaceanimagingbiomarkerforpredictingprognosis